The DOI matches its Crossref record; 468 of the 468 references it cites were found in a registry or an index.
Wnt/β-catenin signaling in cancers and targeted therapies
Open accessAbstract
Wnt/β-catenin signaling has been broadly implicated in human cancers and experimental cancer models of animals. Aberrant activation of Wnt/β-catenin signaling is tightly linked with the increment of prevalence, advancement of malignant progression, development of poor prognostics, and even ascendence of the cancer-associated mortality. Early experimental investigations have proposed the theoretical potential that efficient repression of this signaling might provide promising therapeutic choices in managing various types of cancers. Up to date, many therapies targeting Wnt/β-catenin signaling in cancers have been developed, which is assumed to endow clinicians with new opportunities of developing more satisfactory and precise remedies for cancer patients with aberrant Wnt/β-catenin signaling. However, current facts indicate that the clinical translations of Wnt/β-catenin signaling-dependent targeted therapies have faced un-neglectable crises and challenges. Therefore, in this study, we systematically reviewed the most updated knowledge of Wnt/β-catenin signaling in cancers and relatively targeted therapies to generate a clearer and more accurate awareness of both the developmental stage and underlying limitations of Wnt/β-catenin-targeted therapies in cancers. Insights of this study will help readers better understand the roles of Wnt/β-catenin signaling in cancers and provide insights to acknowledge the current opportunities and challenges of targeting this signaling in cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The inactivation of GSK3β disrupts the integrity and function of the destruction complex, thereby preventing β-catenin phosphorylation. As a result, unphosphorylated, stable β-catenin accumulates in the cytoplasm, translocates to the nucleus, and activates the transcription of its target genes, including c-Myc and Cyclin D1 [35, 46, 47, 52–55].”
From PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma (2026) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Xiu, D., Liu, G., Yu, S., Li, L., Zhao, G.-Q., Liu, L., & Li, X. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1100-8 · Cited by 57
RetractedWu, Y., Tran, T., Dwabe, S., Sarkissyan, M., Kim, J., Nava, M., Clayton, S., Pietras, R. J., Farias‐Eisner, R., & Vadgama, J. V. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4211-y · Cited by 55
RetractedXiu, D., Liu, G., Yu, S., Li, L., Zhao, G.-Q., Liu, L., & Li, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02121-3 · Cited by 44
RetractedLi, H., Yang, T., Ning, Q., Shang, D., Yao, Y., & Sun, Z. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.03.016 · Cited by 3
RetractedComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.275.5307.1787 · Cited by 3,942
β-catenin is a target for the ubiquitin–proteasome pathway
Aberle, H., Bauer, A., Stappert, J., Kispert, A., & Kemler, R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3797 · Cited by 2,529
Research works printed but not linked: 2
- Schwarz-Romond, T. The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat. Struct. Mol. Biol. 14, 484–492 (2007). · DOI · Paper page
- Hoey, T. (ed.) Development of FZD8-Fc (OMP-54 F28), aWnt signaling antagonist that inhibits tumor growth and reduces tumor initiating cell frequency. Presented at AACR Annual Meeting; 2013 April; Washington DC (2013).
Cited by
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
Research progress of glutathione peroxidase family (GPX) in redoxidation
Pei, J., Pan, X., Wei, G., & Hua, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1147414 · Cited by 617
(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Self-citationWnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
Metadata
- Authors
- Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L.
- Affiliations
- Sichuan University (CN)
- Corresponding author
- Ye, Ling
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-08-30
- Volume
- 6
- Issue
- 1
- Pages
- 307-307
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC8403677
- OpenAlex
- W3198051187
- Cited by
- 734
- References
- 468
- Citations by year
- 2026: 106 · 2025: 234 · 2024: 200 · 2023: 139 · 2022: 53 · 2021: 2
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81825005)
- State Key Laboratory of Oral Disease
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- Wnt/β-catenin signaling, cancer, targeted therapy, aberrant signaling, malignant progression, prognosis, clinical translation, treatment resistance
- MeSH terms
- Humans, Neoplasm Proteins, Neoplasms, Wnt Proteins, beta Catenin, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Wnt/β-catenin signaling in cancers and targeted therapies. https://app.cochat.ai/papers/10.1038/s41392-021-00701-5
- The paper
- Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021). Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-021-00701-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.